Given persistent supply constraints from manufacturers struggling to meet demand, semaglutide has remained on shortage lists for extended periods
Immunology 170 , 83104, (2023)
Food and Drug Administration in 2021
5) Who should avoid fat dissolving injections A medical consultation is important, especially if you: are pregnant or breastfeeding have active skin infection, eczema flare, or cold sores in the area have significant autoimmune disease or are immunosuppressed have bleeding disorders or take anticoagulants, unless assessed as appropriate have a history of severe allergies, especially to injectable products Not everyone with a double chin has primarily fat
Aetna's prior authorization criteria for weight-loss-only Wegovy requests require a BMI of 35 or higher higher than the FDA label, which approves Wegovy at BMI 30, or 27 with a weight-related comorbidity